Dual Anti-platelet Therapy in Acute Coronary Syndrome

Abstract

The mortality rate of acute coronary syndrome has been declining over the years. No one can deny that the development and wide use of dual anti-platelet therapy (DAPT) played pivotal role in the decline. The combination of aspirin and P2Y12 inhibitors significantly lowered the recurrent and adverse cardiovascular events in acute coronary syndrome by blocking the primary hemostasis efficiently